Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model

Kenichi Suzuki, Kyoung Sub Kim, You Han Bae

Research output: Contribution to journalArticle

Abstract

Exendin-4 is a glucagon-like peptide-1 (GLP-1) receptor agonist and potent insulinotropic agent for type 2 diabetes patients; however, its therapeutic utility is limited due to the frequent injections required. Long-acting agonists reduce the number of injections, but they can compromise potency. In this study, chondroitin sulfate-g-glycocholic acid-coated and Exendin-4 (Ex-4)-loaded liposomes (EL-CSG) were prepared for oral administration of Ex-4. The Ex-4 loading efficiency was 77% and the loading content in the nanoparticles was 1 wt-%. In rat models, a single oral dose (200 μg/kg) of EL-CSG showed a relative oral bioavailability of 19.5%, compared with subcutaneous administration (20 μg/kg), and sustained pharmacokinetics for up to 72 h. The overall long-term pharmacodynamic effects, assessed by hemoglobin A1c (HbA1c), body weight, and blood lipid concentrations, of daily oral EL-CSG (300 μg/kg) for four weeks were equivalent to or better than daily subcutaneous injections of free Ex-4 solution (20 μg/kg).

LanguageEnglish (US)
Pages259-267
Number of pages9
JournalJournal of Controlled Release
Volume294
DOIs
StatePublished - Jan 28 2019

Fingerprint

Controlled drug delivery
Sulfur Compounds
Biochemistry
Sulfur compounds
Liposomes
Medical problems
Bile Acids and Salts
Type 2 Diabetes Mellitus
Oral Administration
Rats
Pharmacodynamics
Pharmacokinetics
Hemoglobin
Lipids
Peptides
Blood
Nanoparticles
Glycocholic Acid
Acids
Injections

Keywords

  • Bile acid
  • Exendin-4
  • Liposome
  • Liposome intestinal absorption
  • Oral drug delivery
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model. / Suzuki, Kenichi; Kim, Kyoung Sub; Bae, You Han.

In: Journal of Controlled Release, Vol. 294, 28.01.2019, p. 259-267.

Research output: Contribution to journalArticle

@article{e47716972dd64c449906e7065a858d75,
title = "Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model",
abstract = "Exendin-4 is a glucagon-like peptide-1 (GLP-1) receptor agonist and potent insulinotropic agent for type 2 diabetes patients; however, its therapeutic utility is limited due to the frequent injections required. Long-acting agonists reduce the number of injections, but they can compromise potency. In this study, chondroitin sulfate-g-glycocholic acid-coated and Exendin-4 (Ex-4)-loaded liposomes (EL-CSG) were prepared for oral administration of Ex-4. The Ex-4 loading efficiency was 77{\%} and the loading content in the nanoparticles was 1 wt-{\%}. In rat models, a single oral dose (200 μg/kg) of EL-CSG showed a relative oral bioavailability of 19.5{\%}, compared with subcutaneous administration (20 μg/kg), and sustained pharmacokinetics for up to 72 h. The overall long-term pharmacodynamic effects, assessed by hemoglobin A1c (HbA1c), body weight, and blood lipid concentrations, of daily oral EL-CSG (300 μg/kg) for four weeks were equivalent to or better than daily subcutaneous injections of free Ex-4 solution (20 μg/kg).",
keywords = "Bile acid, Exendin-4, Liposome, Liposome intestinal absorption, Oral drug delivery, Type 2 diabetes",
author = "Kenichi Suzuki and Kim, {Kyoung Sub} and Bae, {You Han}",
year = "2019",
month = "1",
day = "28",
doi = "10.1016/j.jconrel.2018.12.028",
language = "English (US)",
volume = "294",
pages = "259--267",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Long-term oral administration of Exendin-4 to control type 2 diabetes in a rat model

AU - Suzuki, Kenichi

AU - Kim, Kyoung Sub

AU - Bae, You Han

PY - 2019/1/28

Y1 - 2019/1/28

N2 - Exendin-4 is a glucagon-like peptide-1 (GLP-1) receptor agonist and potent insulinotropic agent for type 2 diabetes patients; however, its therapeutic utility is limited due to the frequent injections required. Long-acting agonists reduce the number of injections, but they can compromise potency. In this study, chondroitin sulfate-g-glycocholic acid-coated and Exendin-4 (Ex-4)-loaded liposomes (EL-CSG) were prepared for oral administration of Ex-4. The Ex-4 loading efficiency was 77% and the loading content in the nanoparticles was 1 wt-%. In rat models, a single oral dose (200 μg/kg) of EL-CSG showed a relative oral bioavailability of 19.5%, compared with subcutaneous administration (20 μg/kg), and sustained pharmacokinetics for up to 72 h. The overall long-term pharmacodynamic effects, assessed by hemoglobin A1c (HbA1c), body weight, and blood lipid concentrations, of daily oral EL-CSG (300 μg/kg) for four weeks were equivalent to or better than daily subcutaneous injections of free Ex-4 solution (20 μg/kg).

AB - Exendin-4 is a glucagon-like peptide-1 (GLP-1) receptor agonist and potent insulinotropic agent for type 2 diabetes patients; however, its therapeutic utility is limited due to the frequent injections required. Long-acting agonists reduce the number of injections, but they can compromise potency. In this study, chondroitin sulfate-g-glycocholic acid-coated and Exendin-4 (Ex-4)-loaded liposomes (EL-CSG) were prepared for oral administration of Ex-4. The Ex-4 loading efficiency was 77% and the loading content in the nanoparticles was 1 wt-%. In rat models, a single oral dose (200 μg/kg) of EL-CSG showed a relative oral bioavailability of 19.5%, compared with subcutaneous administration (20 μg/kg), and sustained pharmacokinetics for up to 72 h. The overall long-term pharmacodynamic effects, assessed by hemoglobin A1c (HbA1c), body weight, and blood lipid concentrations, of daily oral EL-CSG (300 μg/kg) for four weeks were equivalent to or better than daily subcutaneous injections of free Ex-4 solution (20 μg/kg).

KW - Bile acid

KW - Exendin-4

KW - Liposome

KW - Liposome intestinal absorption

KW - Oral drug delivery

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85058693704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058693704&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2018.12.028

DO - 10.1016/j.jconrel.2018.12.028

M3 - Article

VL - 294

SP - 259

EP - 267

JO - Journal of Controlled Release

T2 - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -